ATP (adenosine triphosphate)

Adenosine 5′-Triphosphate Disodium (ATP): A Comprehensive Reference

1. Identity: Chemical Names, Sources, and Preparations

1.1 Chemical and Systematic Identity

Adenosine triphosphate (ATP) is the primary compound that provides energy to drive many processes in living cells, including muscle contraction, neurotransmission, and cardiac function. As a dietary supplement ingredient, it is most commonly presented in the form of its disodium salt. The full systematic chemical name is adenosine 5′-triphosphate disodium salt (also written adenosine-5′-triphosphate disodium). Additional synonyms include disodium ATP, ATP-Na₂, and adenosine 5′-triphosphoric acid disodium salt. The compound carries the CAS Registry Number 51963-61-2 for the disodium form. Structurally, ATP consists of the purine nucleoside adenosine (adenine base plus ribose sugar) linked to a chain of three phosphate groups; the disodium form replaces two exchangeable protons on the phosphate chain with sodium cations, improving aqueous solubility and stability.

Adenosine triphosphate (ATP) was first discovered in 1929 by the German chemist Karl Lohmann, who isolated ATP from muscle and liver extracts. Found in every cell of the human body, ATP has been dubbed as the "currency of energy" affecting virtually every physiological process requiring energy.

1.2 Natural Occurrence and Biological Sources

ATP is not a botanical-derived ingredient but is a naturally occurring molecule present in all living organisms — animals, plants, fungi, and bacteria. In food, it is found at meaningful concentrations in skeletal muscle (meat and fish) and in cells of all edible plant tissues, though dietary ATP from food is rapidly catabolized during digestion. As a supplement ingredient, the disodium salt is not extracted from natural tissue in commercial quantities. ATP disodium is available commercially and is generally produced through a proprietary fermentation process. The commercially predominant trademarked form, PEAK ATP® (TSI Group Ltd., Missoula, MT, USA), is produced by fermentation.

1.3 Dosage Forms and Common Preparations

Oral administration of ATP is usually in the form of adenosine-5′-triphosphate disodium. Multiple delivery formats have been studied and are commercially available:

• Enteric-coated capsules or pellets: Earlier research used enteric coatings designed to protect ATP from gastric acid and allow release in the small intestine. Initial research used enteric-coated ATP that displayed no apparent efficacy.
• Non-enteric-coated (sublingual or oral) formulations: ATP disodium supplementation has demonstrated improved bioavailability and acute and chronic benefits to cardiovascular health, muscular performance, body composition, and recovery while attenuating muscle breakdown and fatigue. More recent human studies predominantly use non-enteric-coated ATP disodium.
• Flavored powder (stick pack): PeakATP (400 mg adenosine 5′-triphosphate disodium, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, and guar gum) was provided in pre-portioned single serve stick packs in the form of a flavored powder that were similar in taste and appearance.
• Intravenous infusion solutions: Used exclusively in clinical and research settings for cancer and other medical conditions; not a dietary supplement form.

The composition of the dietary supplement may be a powder, a gel, a liquid or may be tabulated or encapsulated.

2. Traditional and Historical Use

ATP disodium in its isolated, supplemental form has no traditional ethnobotanical or pre-modern use. It is a product of twentieth-century biochemical science. As a pure pharmaceutical or nutraceutical compound, its use history begins with clinical pharmacology in the mid-to-late twentieth century, particularly in Europe and Japan.

Oral ATP administration has been shown to have an early acting effect in sub-acute low back pain and has been approved in France as an adjunct in the treatment of lower back pain. This represents the clearest documented precedent for its clinical or regulatory recognition outside the sports supplement context — a pharmaceutical approval in France for musculoskeletal pain, predating its widespread use as a sports performance ingredient in the 2010s.

The intravenous administration of ATP in cancer patients was studied beginning in the 1990s in the Netherlands, particularly by Agteresch and colleagues at Erasmus University Medical Centre Rotterdam, establishing an early clinical research history for the compound. In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life and performance status. These early clinical applications were distinct from oral dietary supplement use and were pursued as a palliative pharmaceutical intervention.

3. Key Constituents and Mechanisms of Action

3.1 Active Compound: ATP and Its Metabolites

The sole active chemical entity in ATP disodium supplements is the adenosine 5′-triphosphate anion (ATP⁴⁻) together with the adenosine metabolites released upon its catabolism. When ATP enters the extracellular environment or is hydrolyzed in the gut lumen, it generates adenosine diphosphate (ADP), adenosine monophosphate (AMP), adenosine, inosine, hypoxanthine, and ultimately uric acid through the purine catabolic cascade.

3.2 Purinergic Signaling: The Primary Mechanistic Pathway

Next to its intracellular role as an energy carrier, ATP and its metabolites function extracellularly as the main ligands involved in purinergic signalling. Purinergic signalling is important for the regulation of inflammation, muscle contraction, neurotransmission and nociception. Extracellular ATP and its metabolites are the main ligands for these receptors.

A fraction of released ATP activates P2 receptors in an autocrine/paracrine fashion. Remaining extracellular ATP undergoes hydrolysis to yield diphosphate nucleotides which activate several P2Y receptors, or is further broken down to produce adenosine, thus activating P1 receptors. In practical terms for supplementation, the proposed mechanism is not that ingested ATP replaces intracellular ATP directly, but that extracellular ATP acts on cell-surface purinergic receptors.

Transient rises in extracellular ATP and its metabolite adenosine have important signaling roles; and acting through purinergic receptors, can increase blood flow and oxygenation of tissues; and act as neurotransmitters.

ATP also has extensive extracellular functions that are primarily mediated through purinergic (P2Y and P2X) membrane receptors ubiquitously present in many cell types. One extracellular-mediated function of ATP includes the modification of muscle excitability (i.e., increasing skeletal muscle calcium permeability and blocking chloride efflux) and vasodilation.

The intestinal epithelium plays a specific role in this pathway. Intestinal epithelial cells play important roles in the absorption of nutrients, secretion of electrolytes and food digestion. The function of these cells is strongly influenced by purinergic signalling activated by extracellular ATP (eATP) and other nucleotides. The activity of several ecto-enzymes determines the dynamic regulation of eATP.

Following extracellular degradation: After being released in the extracellular milieu, ATP is hydrolyzed to adenosine via a sequential series of enzymatic reactions catalyzed by several ecto-nucleotidases: ecto-nucleoside triphosphate diphosphorylases (CD39), ecto-5′-nucleotidase (CD73), ecto-nucleotide pyrophosphatase/phosphodiesterases (NPP) and alkaline phosphatases (APs). Extracellular nucleosides are then taken up by the cells via equilibrative nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs) and ultimately interconverted to generate purine nucleotides by de novo synthesis or via the purine salvage pathway.

Circulating increases in ATP have been observed after injury, which can directly activate the P2Y purinergic receptor, enhancing the recovery of skeletal muscle tissue. This mechanism has been proposed to underpin the anabolic and anti-catabolic effects observed in exercise studies.

3.3 Intracellular Energy Currency Role

It is hypothesized that the improvement in ATP turnover (e.g., prevention of ATP decline or improvement in ATP:ADP ratio) through oral supplementation of ATP could allow athletes to maintain performance through longer periods of exertion and consequently delay the onset of fatigue. Theoretically, this heightened performance would allow for a greater completion of work, which sets the stage for greater exercise training adaptations.

4. Bioavailability: The Central Controversy

The bioavailability of orally administered ATP disodium is one of the most debated topics in this field. The scientific literature is split into two opposing views, and the form of ATP (enteric-coated vs. non-enteric-coated) appears to be a critical determinant.

4.1 Evidence Against Systemic Bioavailability (Enteric-Coated Forms)

Investigators examined whether acute supplementation with oral ATP administered as enteric-coated pellets led to increased concentrations of ATP or its metabolites in the circulation. Eight healthy volunteers participated in a cross-over study. Participants were given in random order single doses of 5000 mg ATP or placebo. To prevent degradation of ATP in the acidic environment of the stomach, the supplement was administered via two types of pH-sensitive, enteric-coated pellets.

ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations. Of all ATP metabolites, only plasma uric acid levels increased significantly after the administration of 5000 mg of ATP. Prolonged administration of ATP was safe as evidenced from liver and kidney parameters. The investigators concluded that oral administration of ATP only resulted in increased uric acid concentrations, and on the basis of these findings, seriously questioned the claimed efficacy of oral ATP at dosages even lower than that used in the present study.

A potential physical chemistry explanation has been proposed for the failure of enteric-coated formulations: One potential explanation for the lack of change in ATP levels after oral administration of enteric-coated ATP could be the buffering capacity of ATP as disodium salt at pH 4.0–4.5. The enteric coating of the ATP disodium requires a pH of 5.5 for dissolution. The enteric coating might only partly dissolve and allow duodenal contents and water to penetrate in the moment of disintegration. As a result, the ATP disodium could keep the pH below 5.5, which would limit the extent to which dissolution occurs, compromising its breakdown and subsequently its release of ATP disodium at the duodenum where it could be absorbed into the bloodstream.

4.2 Evidence for Bioavailability and Extracellular Effects (Disodium Form)

Oral adenosine-5′-triphosphate (ATP) administration has failed to increase plasma ATP levels; however, chronic supplementation with ATP has shown to increase power, strength, lean body mass, and blood flow in trained athletes. This distinction — systemic plasma ATP not rising while peripheral physiological outcomes improve — underlies the hypothesis that the relevant mechanism operates locally in the gut or via splanchnic purinergic signaling rather than through direct delivery of ATP into systemic circulation.

The divergent findings surrounding ATP supplementation and an unidentified mechanism of action continue to preclude stronger conclusions from being made at this time.

5. Scientific Evidence by Health Area

5.1 Skeletal Muscle Performance, Strength, and Hypertrophy

This is the most extensively studied application. Multiple randomized controlled trials (RCTs) and one systematic review and meta-analysis have examined oral ATP disodium in resistance-trained populations.

5.1.1 Systematic Review and Meta-Analysis (2024)

The inclusion criteria required articles published from 2000 to 2022, with anaerobic variables (maximal strength, maximum repetitions, and maximum anaerobic power) measurable in healthy adults with experience in resistance training, only randomized placebo-controlled clinical trials (RCTs), and with acute and/or chronic oral supplementation of ATP. A total of five RCTs with 121 adult men were included. The oral ATP supplementation achieved significantly greater gains in maximal strength compared with the placebo (MD = 8.13 kg, 95%CI [3.36–12.90], p < 0.001). Still, no differences were observed in the maximum number of repetitions or the maximum anaerobic power. Furthermore, 400 mg of ATP showed improvement in anaerobic exercise regardless of the duration of the supplementation protocol. In conclusion, supplementation with 400 mg of ATP doses can improve maximal muscle strength in resistance-trained men.

5.1.2 Wilson et al. (2013) — The Landmark 12-Week RCT

Muscle mass, strength, and power were examined at weeks 0, 4, 8, and 12. There were time and group × time effects for increased total body strength (+55.3 ± 6.0 kg ATP vs. +22.4 ± 7.1 kg placebo, p < 0.001); increased vertical jump power (+796 ± 75 ATP vs. 614 ± 52 watts placebo, p < 0.001); and greater ultrasound-determined muscle thickness (+4.9 ± 1.0 ATP vs. 2.5 ± 0.6 mm placebo, p < 0.02) with ATP supplementation. During the overreaching cycle, there were group × time effects for strength and power, which decreased to a greater extent in the placebo group. Protein breakdown was also lower in the ATP group. The results suggest oral ATP supplementation may enhance muscular adaptations following 12-weeks of resistance training, and prevent decrements in performance following overreaching. No statistically or clinically significant changes in blood chemistry or hematology were observed.

Wilson et al. (2013) reported lower (p = 0.007) protein degradation (determined by urinary 3-methylhistidine) and greater gains in fat-free mass (4 kg vs. 2.5 kg, p = 0.009) and quadriceps' muscle thickness (4.9 mm vs. 2.5 mm, p = 0.020) in the group supplemented with ATP compared with the placebo group at 12 weeks. The dose used was 400 mg/day of ATP disodium (PEAK ATP®).

5.1.3 Overreaching Attenuation

Twelve weeks of oral supplementation with ATP (400 mg/day) in young, resistance-trained males has been shown to attenuate losses of strength and power during a two-week overreaching period (Wilson et al., 2013). In the combinatorial study with HMB-FA: During the overreaching cycle, strength declined in the placebo (−4.5%) group, but this decline was blunted in both the ATP (−2%) and HMB-FA (−0.5%) groups. Surprisingly, the HMB-FA+ATP group continued to gain strength (+1.2%).

5.1.4 Dose-Response Studies

A single 400 mg dose of oral ATP supplementation improved lower body resistance training performance and energy expenditure in recreational resistance-trained males; however, the minimal effective dose is currently unknown. Twenty recreationally trained men consumed a single dose of either 400 mg, 200 mg, or 100 mg ATP (PEAK ATP®) or a placebo in a randomized, placebo-controlled crossover design, separated by a one-week washout between treatments.

The duration of the studies in the meta-analysis ranged from 1 day (a single dose of ATP 30 min before the tests) to 12 weeks. The ingested daily dose of ATP varied from 100 to 400 mg, administered as a disodium salt.

5.1.5 Conflicting and Null Findings

Not all studies have found benefits for anaerobic performance. The results of one study indicated no significant effects of oral supplementation with PeakATP on 3-minute all-out test performance when compared with placebo, while the effect sizes for the performance variables were trivial to small. These findings are consistent with other studies that have shown no beneficial effect of exogenous ATP on anaerobic performance. These findings indicate that 3MT performance was not significantly impacted by PeakATP® supplementation. This may be due in part to the continuous nature of the 3MT, as disodium ATP has been shown to be beneficial for repeated bout activities.

Jordan et al. examined the effects of low dose (150 mg) and high dose (225 mg) ATP supplementation on single Wingate performance both acutely (75 min after ATP ingestion) and following 14 days of supplementation in 27 recreationally active men who were undergoing strength training. They demonstrated that 225 mg of enteric-coated ATP supplementation per day for 15 days provided an increase in total bench-press lifting volume.

Evidence assessment: Evidence for maximal strength gains with chronic 400 mg/day dosing is moderate, based on a meta-analysis of five RCTs (n = 121). All studies to date have been conducted exclusively in resistance-trained adult males, limiting generalizability. Most research comes from one research group, and industry funding has been disclosed in several studies. Benefits for anaerobic power and performance on continuous tasks are not consistently supported.

5.2 Repeated Sprint and Recovery Performance

Fifteen days of 400 mg disodium ATP supplementation resulted in better maintained performance during the latter bouts of repeated bouts of maximal cycling performance compared to placebo supplementation (Purpura et al., 2017).

Oral ATP supplementation prevented a drop in ATP, adenosine-5′-diphosphate (ADP), and adenosine-5′-monophosphate (AMP) levels postexercise (p < 0.05). This study by Purpura et al. (2017) enrolled trained athletes in a randomized, double-blind, placebo-controlled design examining 400 mg ATP administered for 15 days prior to and acutely before a repeated sprint bout.

5.3 Blood Flow and Cardiovascular Health

In a pilot study, 12 college-aged resistance-trained subjects were given 400 mg of ATP (Peak ATP®) daily for 12 weeks, and prior to an acute arm exercise bout at weeks 1, 4, 8, and 12. Oral ATP administration can increase post-exercise blood flow, and may be particularly effective during exercise recovery.

After 0, 1, 4, 8, and 12 weeks of supplementation, blood flow changes in the brachial artery were assessed using flow-mediated dilation in conjunction with an acute upper-arm exercise protocol. Blood flow and brachial artery diameter significantly increased when ATP supplementation was provided, but the lack of a control group in this study compromises the ability to more fully understand the potential of ATP to impact blood flow.

In a hypertensive population: Acute and long-term benefits of ATP supplementation on cardiovascular health in non-athletic populations have been reported. Oral adenosine 5′-triphosphate supplementation improved hemodynamic and autonomic parameters after exercise in hypertensive women, in a study published in the Journal of Exercise Rehabilitation (2018).

Evidence assessment: Blood flow improvements are mechanistically plausible via vasodilatory purinergic signaling. Early human data are positive but predominantly from small, uncontrolled, or pilot studies. Larger, adequately controlled trials specifically designed for cardiovascular endpoints are lacking.

5.4 Lower Back Pain

Oral ATP supplementation at a dosage of 90 mg/day significantly reduced participants' self-assessment of their disability levels and reduced the usage of rescue analgesics in 181 men and women with category 1 or 2 subacute lower back pain (Bannwarth et al., 2005). In a separate publication from the same research group, patients who supplemented with ATP were three times less likely to report a condition that had worsened or remained unimproved and took fewer rescue drugs (Rossignol et al., 2005).

This clinical program was conducted in France across primary care settings. The objective was to study the effect of the guidelines' advice to remain active, alone and with the addition of the drug adenosine tri-phosphate (ATP), in patients with subacute low-back pain. A drug-guidelines effectiveness trial was undertaken simultaneously to an experimental drug efficacy placebo-controlled trial in subacute (4–12 weeks) non-specific low-back pain patients.

Patients in the group receiving guidelines plus ATP were three times less likely to report a condition that had worsened or remained unimproved at 90 days (p = 0.02). This drug-guidelines effectiveness trial showed a modest advantage of combined specific pharmacologic and non-pharmacological treatments on absolute improvement. A threefold reduction in the risk of chronicity was observed, an important goal in low-back pain guidelines.

Evidence assessment: Two published clinical trials in France support a benefit at 90 mg/day for subacute low back pain. This led to regulatory recognition in France. The mechanism proposed involves musculoskeletal purinergic receptor activation and increased tissue blood flow. Evidence is limited to this specific indication at a substantially lower dose than used in sports studies.

5.5 Cancer Cachexia and Quality of Life (Intravenous Route)

Multiple clinical trials investigated intravenous ATP infusion in advanced cancer patients. These are not oral supplement studies but represent the earliest controlled human clinical data on ATP administration.

In nonrandomized studies involving patients with different tumor types including non-small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and deterioration of quality of life and performance status. Agteresch and colleagues conducted a randomized clinical trial to evaluate the effects of ATP in patients with advanced NSCLC (stage IIIB or IV). Fifty-eight patients were randomly assigned to receive either 10 intravenous 30-hour ATP infusions, with the infusions given at 2- to 4-week intervals, or no ATP. Outcome parameters were assessed every 4 weeks until 28 weeks.

In this subsequent randomized trial in patients with advanced (stage IIIB or IV) non-small-cell lung cancer, intravenous ATP reduced weight loss (1.0 kg to 0.2 kg/month) and reversed decreases in serum albumin, elbow flexor muscle strength, and quality of life measures.

Cancer cachexia is associated with elevated lipolysis, proteolysis and gluconeogenesis. ATP infusion has been found to significantly inhibit loss of body weight, fat mass and fat-free mass in patients with advanced lung cancer.

A previous study in patients with advanced non-small-cell lung cancer showed that adenosine 5′-triphosphate (ATP) infusions had a favourable effect on fatigue, appetite, body weight, muscle strength, functional status and quality of life.

Most ATP courses in this group of cancer patients were without side effects (64%), and side effects occurring in the remaining courses were mild and transient, resolving within minutes after decreasing the infusion rate.

Evidence assessment: The intravenous cancer cachexia data constitute the most rigorously randomized human evidence for physiological effects of exogenous ATP. However, intravenous and oral routes are pharmacologically distinct, and these results should not be extrapolated uncritically to oral supplementation. Severe adverse events were recorded in some intravenous protocols at high infusion rates.

5.6 Strength Training Performance in a Single Acute Session

Freitas and investigators examined the impact of a single 400 mg dose of non-enteric coated ATP in a randomized, double-blind, crossover study design in 11 healthy, previously active males. Thirty minutes after ingestion, participants completed a series of half-squat repetitions with 80% of their 1RM. Performance was recorded as total repetitions completed, and oxygen consumption, lactate and hemodynamic parameters were also assessed. In comparison to placebo, the total weight lifted was significantly increased (Placebo: 3995.7 ± 1137.8 vs. ATP: 4967.4 ± 1497.9 kg, p = 0.005) when the ATP dose was provided.

5.7 Neurological Conditions (Preliminary)

In a pediatric case study of a child with alternating hemiplegia, an intractable neurological disorder, reported that oral ATP supplementation reduced both the frequency and duration of hemiplegic episodes. While the results of these early studies are promising, additional studies on oral ATP supplementation in clinical conditions are warranted. This finding is based on a single case report and cannot be used to draw clinical conclusions.

6. Body Systems and Health Areas Associated with ATP Supplementation

• Musculoskeletal system: Skeletal muscle performance, strength, hypertrophy, protein catabolism (attenuation), and fatigue resistance during high-intensity resistance exercise.
• Cardiovascular system: ATP is involved in all aspects of biosynthesis in cells and acts as the primary intracellular energy source. Extracellular ATP and its metabolites are involved in regulating a variety of biological processes including cardiac function, neurotransmission, liver glycogen metabolism, muscle contraction and blood flow. Vasodilation and brachial blood flow have been studied in both athletes and hypertensive women.
• Musculoskeletal pain system: Sub-acute low back pain, with clinical evidence from French RCTs.
• Metabolic/anabolic pathways: Purine salvage pathways, purinergic receptor-mediated anabolic signaling in skeletal muscle tissue.
• Oncology / supportive care: Cancer cachexia and quality of life maintenance in advanced lung cancer patients (intravenous route).
• Immune and inflammatory signaling (preclinical): The dysregulation of the purinergic signaling has been associated with important pathophysiological conditions including neurodegenerative diseases, cancer, inflammation and metabolic disorders such as obesity. These are mechanistic associations from the purinergic signaling literature and have not been translated to clinical supplement outcomes.

7. Dosages Reported in Clinical Studies

The following dosages are reported exactly as documented in published clinical research:

• 90 mg/day (oral): Oral ATP supplementation at a dosage of 90 mg/day significantly reduced participant's self-assessment of their disability levels and reduced the usage of rescue analgesics in 181 men and women with category 1 or 2 subacute lower back pain (Bannwarth et al., 2005).
• 150 mg and 225 mg/day (oral, enteric-coated): Jordan et al. examined the effects of low dose (150 mg) and high dose (225 mg) ATP supplementation on single Wingate performance both acutely and following 14 days of supplementation in 27 recreationally active men who were undergoing strength training.
• 400 mg/day (oral, non-enteric-coated disodium salt): The most common dose in sports nutrition studies. In a study where 12 weeks of resistance training exercise was combined with 400 mg of disodium ATP supplementation in healthy, resistance-trained males, ATP supplementation resulted in significantly greater increases in lean mass, muscle thickness, maximal strength, and vertical jump power in comparison to exercise alone. Also used in cardiovascular blood flow studies and the repeated sprint Purpura et al. (2017) trial.
• 250 mg, 1,250 mg, and 5,000 mg/day (oral, enteric-coated pellets, for bioavailability assessment): Thirty-two healthy subjects were randomised to receive 0, 250, 1,250 or 5,000 mg ATP per day for 28 days by means of enteric-coated pellets. In addition, on days 0 and 28, all thirty-two subjects received 5,000 mg ATP to determine whether prolonged administration would induce adaptations in the bioavailability of ATP.
• 5,000 mg (single acute dose, enteric-coated pellets): Participants were given in random order single doses of 5,000 mg ATP or placebo.
• Animal model (rat gavage, human-equivalent doses of 100, 400, 1,000, and 1,600 mg): Male Wistar rats were gavage-fed the body surface area, species adjusted human equivalent dose (HED) of either 100 mg (n=4), 400 mg (n=4), 1,000 mg (n=5) or 1,600 mg (n=5) of oral ATP as a disodium salt. Rats that were not gavage-fed were used as controls. Blood flow was monitored continuously prior to, during and following an electrically-evoked leg-kicking exercise.
• Intravenous (cancer research only, not for supplementation): Intravenous infusion of ATP for 96 hours at 28-day intervals at doses of 50 µg/kg/min to patients with advanced non-small cell lung cancer increased ATP pools in red blood cells, inhibited weight loss, reduced cachexia, and improved survival. Fifty-eight patients were randomly assigned to receive either 10 intravenous 30-hour ATP infusions, with the infusions given at 2- to 4-week intervals.

In clinical sports research, the duration of the studies ranged from 1 day (a single dose of ATP 30 min before the tests) to 12 weeks, and the ingested daily dose of ATP varied from 100 to 400 mg, administered as a disodium salt.

8. Safety Considerations and Toxicology

8.1 Subchronic Animal Toxicology

In a 90-day repeated dose toxicology study, ATP disodium salt was administered by gavage to rats for 90 consecutive days at doses of 0 (control), 500, 1,000, and 2,000 mg/kg BW/day (n = 10 per sex/group). Results support the safety of ATP as a functional food agent or dietary supplement.

Subchronic administration of ATP was well tolerated at all dose levels. Body weights and feed consumption body weight gains were similar between ATP-treated and control rats. Minor differences were seen in hematology and blood chemistry; however, these changes were not dose-related and therefore not of biological or toxicological significance. Only one difference was observed in absolute organ weights: females of the high-dose group had increased kidney and increased relative kidney and liver weights; however, these differences were not seen in males nor appeared to be dose-related.

8.2 Human Clinical Safety Data

In the 12-week Wilson et al. (2013) RCT, no statistically or clinically significant changes in blood chemistry or hematology were observed. This finding is consistent across the broader clinical literature.

The systematic review and meta-analysis confirmed that daily intakes of 400 mg of ATP for periods up to 12 weeks are safe in healthy subjects.

Prolonged administration of ATP was safe as evidenced from liver and kidney parameters in the Arts et al. (2012) 4-week study in healthy volunteers.

8.3 Uric Acid Elevation: A Documented Concern at High Doses

Because ATP is a purine nucleotide, its catabolism generates uric acid through the xanthine oxidase pathway. This is the most consistently documented metabolic side effect, specifically at very high doses. ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations. Of all ATP metabolites, only plasma uric acid levels increased significantly after the administration of 5,000 mg of ATP. Importantly, this elevation was observed at 5,000 mg/day — far above the 400 mg/day dose used in sports supplement studies — and was not observed at lower doses in these trials. Individuals with gout, hyperuricemia, or a history of uric acid kidney stones should be aware of this dose-dependent metabolic consideration.

8.4 Intravenous Route — Specific Adverse Events

Adverse event data from oral supplement studies at 400 mg/day are generally favorable, but the intravenous research context reveals pharmacologically relevant safety signals at high infusion rates. Such a protocol includes continuous intravenous infusions of ATP for periods longer than 24 hours during which time the patient is being hospitalized. The continuous infusions are administered for multiple treatment cycles every 2–4 weeks. During these infusion protocols some grades 3 and 4 (severe and life-threatening) toxicity have been recorded. These findings apply exclusively to intravenous administration at pharmacological doses and are not directly translatable to oral dietary supplement use.

8.5 Potential Drug Interactions

ATP and its metabolite adenosine have known cardiovascular electrophysiological effects. Extracellular adenosine 5′-triphosphate (ATP) is involved in the regulation of a variety of biological processes, including neurotransmission, muscle contraction, and liver glucose metabolism, via purinergic receptors. Clinically, adenosine itself (a breakdown product of ATP) is used as an intravenous antiarrhythmic agent, and drugs that affect adenosine metabolism or purinergic receptor activity (e.g., methylxanthines such as caffeine and theophylline, which are adenosine receptor antagonists) may theoretically modulate the pharmacological effects of exogenous ATP. However, no controlled human drug-interaction studies for oral ATP disodium supplementation have been identified in the peer-reviewed literature.

Individuals taking xanthine oxidase inhibitors (e.g., allopurinol or febuxostat for gout) may show altered purine metabolite profiles when taking high doses of ATP, though this interaction has not been studied in controlled trials at supplement-range doses.

8.6 Regulatory and Classification Status

Oral ATP disodium (adenosine 5′-triphosphate disodium) is a commercially available product available alone and as a constituent in a number of sports supplements that is purported to maintain ATP levels and improve performance during high-intensity exercise. It is classified as a dietary supplement ingredient in the United States. In France, as noted, it has also been used as an approved drug for sub-acute low back pain, reflecting dual regulatory status in different jurisdictions.

9. Limitations and Research Gaps

Several important caveats limit confidence in the current body of evidence:

• The predominant research on sports performance benefits comes from a small number of research groups with disclosed industry relationships; independent replication is limited.
• Nearly all sports performance RCTs were conducted exclusively in resistance-trained adult males; results cannot be generalized to women, older adults, or untrained populations without further evidence.
• The divergent findings surrounding ATP supplementation and an unidentified mechanism of action continue to preclude stronger conclusions from being made at this time.
• The contrast between studies showing no increase in plasma ATP (Arts et al., 2012; British Journal of Nutrition study) yet functional benefits in performance and blood flow trials has not been fully resolved mechanistically.
• Long-term safety data (beyond 90-day animal studies and 12-week human trials) are not available.
• Dose optimization for different outcomes (pain vs. performance vs. cardiovascular) has not been systematically characterized in controlled human trials.

References

• Jäger R, Purpura M, Rathmacher JA, et al. Health and ergogenic potential of oral adenosine-5′-triphosphate (ATP) supplementation. Journal of Functional Foods. 2021;78:104357.
• Jäger R, Purpura M, Fuller JC. Subchronic (90-Day) repeated dose toxicity study of disodium adenosine-5′-triphosphate in rats. Regulatory Toxicology and Pharmacology. 2020;116:104760.
• Arts ICW, Coolen EJCM, Bours MJL, et al. Adenosine 5′-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebo-controlled cross-over trial in healthy humans. Journal of the International Society of Sports Nutrition. 2012;9:16.
• Systemic review and meta-analysis: The Effect of Oral Adenosine Triphosphate (ATP) Supplementation on Anaerobic Exercise in Healthy Resistance-Trained Individuals. PMC. 2024.
• Wilson JM, Joy JM, Lowery RP, et al. Effects of oral adenosine-5′-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men. Nutrition & Metabolism. 2013;10(1):57.
• Purpura M, Rathmacher JA, Sharp MH, et al. Oral Adenosine-5′-triphosphate (ATP) Administration Increases Postexercise ATP Levels, Muscle Excitability, and Athletic Performance Following a Repeated Sprint Bout. Journal of the American College of Nutrition. 2017;36(3):177–183.
• Dose Response of Acute ATP Supplementation on Strength Training Performance. Frontiers in Sports and Active Living. 2021.
• The Effects of Two Weeks of Oral PeakATP® Supplementation on Performance during a Three-Minute All out Test. PMC. 2023.
• Oral adenosine-5′-triphosphate (ATP) administration increases blood flow following exercise in animals and humans. PMC / Journal of the International Society of Sports Nutrition. 2014.
• Agteresch HJ, Dagnelie PC, van der Gaast A, et al. Randomized Clinical Trial of Adenosine 5′-Triphosphate in Patients With Advanced Non-Small-Cell Lung Cancer. JNCI: Journal of the National Cancer Institute. 2000;92(4):321–328.
• Application of adenosine 5′-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial. BMC Public Health. 2007.
• Agteresch HJ, et al. Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer. PubMed. 2000.
• Rossignol M, Allaert FA, Rozenberg S, et al. Measuring the contribution of pharmacological treatment to advice to stay active in patients with subacute low-back pain: a randomised controlled trial. Pharmacoepidemiology and Drug Safety. 2005;14:861–867.
• Oral bioavailability of ATP after prolonged administration. British Journal of Nutrition. 2011.
• Lowery RP, Joy JM, Rathmacher JA, et al. Effects of 12 weeks of beta-hydroxy-beta-methylbutyrate free acid, adenosine triphosphate, or a combination on muscle mass, strength, and power in resistance trained individuals. PMC / Journal of the International Society of Sports Nutrition. 2013.
• From purines to purinergic signalling: molecular functions and human diseases. Signal Transduction and Targeted Therapy. 2021.
• Metabolic Changes Induced by Purinergic Signaling: Role in Food Intake. Frontiers in Pharmacology. 2021.
• Dynamic recycling of extracellular ATP in human epithelial intestinal cells. PLOS Computational Biology / PMC. 2023.
• Effect of PeakATP on Mood, Reaction Time and Cognition. ClinicalTrials.gov NCT05100589.